作者
Paul C Tumeh, Matthew D Hellmann, Omid Hamid, Katy K Tsai, Kimberly L Loo, Matthew A Gubens, Michael Rosenblum, Christina L Harview, Janis M Taube, Nathan Handley, Neharika Khurana, Adi Nosrati, Matthew F Krummel, Andrew Tucker, Eduardo V Sosa, Phillip J Sanchez, Nooriel Banayan, Juan C Osorio, Dan L Nguyen-Kim, Jeremy Chang, I Peter Shintaku, Peter D Boasberg, Emma J Taylor, Pamela N Munster, Alain P Algazi, Bartosz Chmielowski, Reinhard Dummer, Tristan R Grogan, David Elashoff, Jimmy Hwang, Simone M Goldinger, Edward B Garon, Robert H Pierce, Adil Daud
发表日期
2017/5/1
期刊
Cancer immunology research
卷号
5
期号
5
页码范围
417-424
出版商
American Association for Cancer Research
简介
We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non–small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival [PFS; objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared with patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (OR, 1.852; P < 0.0001). In a subset of biopsied patients (n = 62), liver …
学术搜索中的文章
PC Tumeh, MD Hellmann, O Hamid, KK Tsai, KL Loo… - Cancer immunology research, 2017